{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["14(12)"],"submitter":["Wen X"],"pubmed_abstract":["<h4>Background</h4>Accurate assessment of pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) in breast cancer (BC) is crucial for mitigating chemotherapy-related toxicity in patients who do not respond to the treatment. Conventional ultrasound (US) has become a pivotal method for evaluating treatment response due to its cost-effectiveness, convenience, and absence of ionizing radiation. The objective of this study was to develop a model combining US and clinicopathological characteristics at baseline, as well as US features after one cycle of NAC, to predict the pCR to NAC in BC.<h4>Methods</h4>This retrospective study included 74 patients with invasive BC who underwent NAC from January 2022 to December 2023. Data from US and clinicopathological characteristics before N"],"journal":["Quantitative imaging in medicine and surgery"],"pagination":["8840-8851"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11652014"],"repository":["biostudies-literature"],"pubmed_title":["Model based on ultrasound and clinicopathological characteristics for early prediction of pathological complete response to neoadjuvant chemotherapy in breast cancer."],"pmcid":["PMC11652014"],"pubmed_authors":["Deng B","Wen X","Chen J","Lin Y","Su Z","Zhong J","Zhuang Y"],"additional_accession":[]},"is_claimable":false,"name":"Model based on ultrasound and clinicopathological characteristics for early prediction of pathological complete response to neoadjuvant chemotherapy in breast cancer.","description":"<h4>Background</h4>Accurate assessment of pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) in breast cancer (BC) is crucial for mitigating chemotherapy-related toxicity in patients who do not respond to the treatment. Conventional ultrasound (US) has become a pivotal method for evaluating treatment response due to its cost-effectiveness, convenience, and absence of ionizing radiation. The objective of this study was to develop a model combining US and clinicopathological characteristics at baseline, as well as US features after one cycle of NAC, to predict the pCR to NAC in BC.<h4>Methods</h4>This retrospective study included 74 patients with invasive BC who underwent NAC from January 2022 to December 2023. Data from US and clinicopathological characteristics before N","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Dec","modification":"2025-04-03T23:08:49.446Z","creation":"2025-04-03T23:08:49.446Z"},"accession":"S-EPMC11652014","cross_references":{"pubmed":["39698713"],"doi":["10.21037/qims-24-1268"]}}